Philipp M Cromm

Title: Innovations of Philipp M Cromm in Proteolysis Modulation

Introduction

Philipp M Cromm is an accomplished inventor based in New Haven, CT (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that modulate proteolysis. With a total of 2 patents, his work focuses on innovative solutions for targeted ubiquitination.

Latest Patents

Cromm's latest patents include groundbreaking research on imide-based modulators of proteolysis. These patents describe imide-based compounds, including bifunctional compounds, which serve as modulators of targeted ubiquitination. The compounds are designed to inhibit various polypeptides and proteins that are degraded or inhibited by these bifunctional compounds. Specifically, the compounds feature a ligand that binds to the cereblon E3 ubiquitin ligase on one end and a moiety that binds a target protein on the other end. This design allows the target protein to be positioned near the ubiquitin ligase, facilitating its degradation and inhibition. The compounds can be synthesized to exhibit a wide range of pharmacological activities, making them versatile tools in the degradation and inhibition of targeted polypeptides.

Career Highlights

Philipp M Cromm is affiliated with Yale University, where he continues to advance his research in biochemistry and pharmacology. His innovative work has garnered attention in the scientific community, contributing to the understanding of protein degradation mechanisms.

Collaborations

Cromm collaborates with notable colleagues, including Craig M Crews and George Burslem, who share his passion for advancing research in the field of proteolysis modulation.

Conclusion

Philipp M Cromm's contributions to the field of biochemistry through his innovative patents on imide-based modulators of proteolysis highlight his role as a leading inventor. His work not only enhances the understanding of protein degradation but also opens new avenues for therapeutic applications.